Evidence map›Paper›PMID 40711443›Full record

ArticleEuropean journal of immunology2025

Machine Learning Reassessment of Serum Immune Factors Shows No Unique Immune Profiles Linked to Disease Outcomes in SARS-CoV-2-infected Patients at Hospital Admittance.

Stefania Rossi, Imerio Capone, Enrico Cabri, Anna Giabelli, Ilaria Rossoni, Giulia Romagnoli, Stefano M Santini, Cinzia Marcantonio, Roberto Giuseppetti, Umbertina Villano and 10 more

Abstract read
In one paragraph

Article in European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Stefania RossiDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0002-8854-7072
Imerio CaponeDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Enrico CabriIstituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.
Anna GiabelliIstituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.
Ilaria RossoniIstituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.
Giulia RomagnoliDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Stefano M SantiniDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.
Cinzia MarcantonioDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Roberto GiuseppettiDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Umbertina VillanoDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Roberto BruniDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Anna R CiccaglioneDepartment of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy.
Federica FrascaDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.
Alessandra d'AuriaDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.
Ginevra BuganiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Gabriella d'EttorreDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy.
Guido AntonelliDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.
Carolina ScagnolariDepartment of Molecular Medicine, Laboratory of Virology, Sapienza University of Rome, Rome, Italy.ORCID 0000-0003-1044-1478
Maddalena FratelliIstituto di Ricerche Farmacologiche "Mario Negri" IRCCS, Milan, Italy.
Lucia GabrieleDepartment of Oncology and Molecular Medicine, Istituto Superiore di Sanità, Rome, Italy.ORCID 0000-0002-1483-866X

Funding

European Union-NextGeneration EUFondo di Beneficenza di Intesa Sanpaolo 2020Italian Ministry of University and Research
6 · The paper itself

Abstract

The complex pathophysiology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) involves a hyperinflammatory state with excessive cytokine production, leading to an influenza-like syndrome that may need emergency care. The severity of SARS-CoV-2 varies widely, and collective serum immune factors, evaluated in emergency care patients, have not been shown to correlate with disease progression. We applied a machine learning approach to reassess and define serum immune profiles that could align with clinical laboratory parameters and predict disease outcomes in patients with respiratory virus infections, including those with SARS-CoV-2, seeking emergency care. Sixty-two plasma immune molecules, in a cohort of 67 symptomatic SARS-CoV-2, were analyzed for correlation with antibodies (Abs) to spike (S) and nucleocapsid (N) proteins, as well as with clinical laboratory parameters, to identify early indicators of disease prognosis at hospital admission. This approach allowed us to analyze and cluster unlabeled datasets, delineating three distinct serum immune signatures. Two showed significant and opposite modulations, correlating with poorer disease outcomes, while most patients with moderate disease displayed modest immune factor dysregulation. This highlights the complexity of immune responses in the severity of diseases caused by highly respiratory pathogenic virus like SARS-CoV-2, emphasizing the importance of evaluating overall immune imbalance rather than focusing on a few dysregulated factors.

Indexed as

COVID-19Machine LearningSARS-CoV-2AdultAgedAntibodies, ViralCoronavirus Nucleocapsid ProteinsFemaleHospitalizationHumansMaleMiddle AgedPhosphoproteinsPrognosisSpike Glycoprotein, CoronavirusAntibodies, ViralCoronavirus Nucleocapsid Proteinsnucleocapsid phosphoprotein, SARS-CoV-2PhosphoproteinsSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID‐19cytokinesinfectioninflammationmachine learning

Identifiers

PMID40711443
PMCPMC12292737

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.